

ENVIRONMENT, PUBLIC HEALTH AND FOOD SAFETY (ENVI) - HEALTH WORKING GROUP

Workshop on cancer prevention - modifiable risk factors

18 February 2020, 12.30 - 14.00

Speaker's bio

✓ Dr Joachim Schüz



Dr Joachim Schüz is a **senior cancer epidemiologist**. Since 2010 he is **Head of the Section of Environment and Radiation at the International Agency for Research on Cancer (IARC), the cancer research agency of the World Health Organisation (WHO)**, in Lyon, France. Objectives of research in the Section is the identification of causes of cancer related to environmental pollutants, occupational exposures, some lifestyle factors, and radiations (ionizing and non-ionizing). In 2020 he additionally became Acting Head of the Section of Early Detection and

Prevention at the IARC, with the objectives of implementation research on cancer prevention.

Related to cancer prevention, Dr Schüz is **Chair of the newly established network "Cancer Prevention Europe"**, a consortium of key cancer prevention institutions in Europe, **and is leading the 4th edition of the European Code against Cancer**. Before moving to the IARC, Dr Schüz was working at the Danish Cancer Society Research Center in Copenhagen and at the University of Mainz, Germany, where he received his PhD in 1997 and his professorial qualifications (Habilitation) in 2002. Dr Schüz worked in the field of cancer epidemiology throughout his career and has authored/co-authored more than 300 peer-reviewed scientific publications. Noteworthy related to the EC is his former membership in the Scientific Committee on Newly Identified Health Risks (SCENIHR).

✓ Stefan Gijssels



Stefan Gijssels is **Executive Director and Member of the Board of Digestive Cancers Europe, the umbrella organisation of all digestive cancer patient associations in Europe** (oesophageal, gastric, pancreatic, colon, rectum and rare digestive cancers). The organisation represents 30 national associations. In this capacity, he is also member of the European Commission's Innovative Partnership for Action Against Cancer (iPAAC), and of the European Reference Network of Rare

Cancers (EURACAN).

Stefan is a metastatic colon cancer survivor.

Since 2016, he also works as an independent health policy advisor, publicist, facilitator and moderator, working for public health authorities, patient organisations and industry.

Until 2016, he was Vice President Communication & Public Affairs and Janssen Europe, Middle East & Africa. He was the Vice-Chairman of the Belgian Federal Science Policy Council, Member of the Board of the Flemish Institute for Science & Technology Aspects (an advisory committee for the Flemish Parliament). In the 90s he was director and general manager at Burson-Marsteller, Vice-President at Weber-Shandwick, Public Affairs Manager at McDonald's, and Project Manager at the Institute of the Enterprise, a Belgian policy think tank. He started his career as an English teacher in Morocco. He has a master's degree in Linguistics and Literature from Leuven University, Belgium.

✓ **Professor Daniel Kelly**



Professor Kelly is the holder of the **Royal College of Nursing Chair of Nursing Research at Cardiff University**.

He is Past-President of the European Oncology Nursing Society and former board member of ECCO. His professional background is in **Cancer nursing and sexual health**. He leads research on a national and international level on cancer related projects and has published widely. His interest in preventing HPV related cancers stem from his work in cancer care and his ambition to raise

awareness of HPV vaccination as a safe, effective and inexpensive intervention available for young people in all countries.

✓ **Professor Pamela Kearns**



Pamela Kearns is **Professor of Clinical Paediatric Oncology at the Institute of Cancer and Genomic Sciences (University of Birmingham)** and **Honorary Consultant in Paediatric Oncology at Birmingham Children's Hospital**. She is **Director of the Cancer Research UK Clinical Trials Unit (University of Birmingham)** delivering a wide-ranging programme of clinical trials across all types of cancer in all age groups, notably leading the Cancer Research UK funded National

Children's Cancer Trials Team. In 2015, she was appointed as a Senior Clinical Advisor to Cancer Research UK.

In 1982 Professor Kearns was awarded a BSc (Hons) in Physiology from the University of Aberdeen where she subsequently studied Medicine qualifying in 1988. She was awarded a PhD in leukaemia biology from the Newcastle University in 2000, where she also completed her postgraduate training in paediatric oncology. She was appointed Senior Lecturer/Honorary Consultant in Paediatric Oncology at the University of Bristol

in 2002 and moved to Birmingham in 2007, where she further developed her research in childhood acute leukaemias and lymphomas, focused on pre-clinical models and early phase drug development trials for evaluation of novel therapies. She was elected Fellow of the Royal College of Paediatrics and Child Health in 2009.

Professor Kearns is the **President of the European Society for Paediatric Oncology (SIOP Europe)** and a member of the Board for both the European consortium for Innovative Therapeutics for Children with Cancer (ITCC); a consortium developing early phase clinical trials for childhood cancers through International partnerships and ACCELERATE; a multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. She was actively engaged in raising awareness of the regulatory challenges facing academic trials for children with cancer; supporting crucial amendments to the upcoming EU Clinical Trial Regulation that will benefit both adult and childhood cancer trials when it is implemented.